Benchmark analyst Robert Wasserman raised the firm’s price target on Halozyme (HALO) to $68 from $55 and keeps a Buy rating on the shares on growing earnings momentum as well as anticipation of pending U.S. approval of Argenx’s (ARGX) subcutaneous Vyvgart for generalized Myasthenia Gravis, or gMG.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO: